or
forgot password

A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML


Phase 1/Phase 2
18 Years
90 Years
Open (Enrolling)
Both
Acute Myeloid Leukemia

Thank you

Trial Information

A Phase I/II Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed AML


In the Phase I portion of the study patients with a diagnosis of AML who have relapsed
disease will be treated with an assigned number of doses of 5 azacitidine followed by
Mylotarg administered two times over two weeks

In the Phase II portion of the study patients will be treated with the dose of 5azacitidine
determined to be safe in the Phase I portion of the study followed by Mylotarg.

A sample of blood or bone marrow will be obtained prior to initiation of treatment and
another sample obtained after treatment with 5-azacitidine but before Mylotarg and the
samples will be tested in the laboratory to determine response to treatment.


Inclusion Criteria:



- Diagnosis of Relapsed AML

- ECOG performance status 0-2, and life expectancy > 3 months

- ≥ 18 years old

- Previously untreated for current AML relapse

- Adequate organ function

- Written informed consent

Exclusion Criteria:

- Pregnant or breast-feeding women

- Growth factors that support platelet or white cell number or function must not have
been administered within the past 7 days

- Currently receiving another investigational drug

- Currently receiving other anti-cancer agents

- Uncontrolled infection

- HIV positive

- Received previous therapy with either Mylotarg or 5-azacitidine

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

In Phase I the Maximum Tolerated Dose will be the maximum dose at which fewer than one-third of patients experience Dose Limiting Toxicity

Outcome Time Frame:

approximately 4 years

Safety Issue:

Yes

Authority:

United States: Institutional Review Board

Study ID:

090516

NCT ID:

NCT00766116

Start Date:

July 2005

Completion Date:

May 2014

Related Keywords:

  • Acute Myeloid Leukemia
  • AML
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location
Stanford University Stanford, California  94305
Northside Hospital/BMTGA Atlanta, Georgia  30342